Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea

N/ACompletedNCT02010788

Allergan523 enrolled

Overview

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB) not adequately controlled by anticholinergic drugs.

Study Type

OBSERVATIONAL

Enrollment

523

Conditions

Urinary Incontinence Urinary Bladder, Overactive

Interventions

botulinum toxin Type ABIOLOGICAL

Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: -Patients with urinary incontinence due to NDO or OAB treated with BOTOX® as per local standard of care in clinical practice. Exclusion Criteria: -None.

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Number of Participants with Adverse Events and Adverse Drug Reactions

Time frame: 4 Months

International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) Total Score

Time frame: 4 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.